BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 23296407)

  • 1. Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials.
    Brown JR
    Curr Hematol Malig Rep; 2013 Mar; 8(1):1-6. PubMed ID: 23296407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibrutinib treatment of CLL: the cancer fights back.
    Young RM; Staudt LM
    Cancer Cell; 2014 Jul; 26(1):11-3. PubMed ID: 25026208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibition.
    Dias AL; Jain D
    Cardiovasc Hematol Agents Med Chem; 2013 Dec; 11(4):265-71. PubMed ID: 24433470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
    Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum KA; Grant B; Sharman JP; Coleman M; Wierda WG; Jones JA; Zhao W; Heerema NA; Johnson AJ; Sukbuntherng J; Chang BY; Clow F; Hedrick E; Buggy JJ; James DF; O'Brien S
    N Engl J Med; 2013 Jul; 369(1):32-42. PubMed ID: 23782158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.
    Davids MS; Brown JR
    Future Oncol; 2014 May; 10(6):957-67. PubMed ID: 24941982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
    Woyach JA; Furman RR; Liu TM; Ozer HG; Zapatka M; Ruppert AS; Xue L; Li DH; Steggerda SM; Versele M; Dave SS; Zhang J; Yilmaz AS; Jaglowski SM; Blum KA; Lozanski A; Lozanski G; James DF; Barrientos JC; Lichter P; Stilgenbauer S; Buggy JJ; Chang BY; Johnson AJ; Byrd JC
    N Engl J Med; 2014 Jun; 370(24):2286-94. PubMed ID: 24869598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Tran PN; O'Brien S
    Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).
    Woyach JA; Bojnik E; Ruppert AS; Stefanovski MR; Goettl VM; Smucker KA; Smith LL; Dubovsky JA; Towns WH; MacMurray J; Harrington BK; Davis ME; Gobessi S; Laurenti L; Chang BY; Buggy JJ; Efremov DG; Byrd JC; Johnson AJ
    Blood; 2014 Feb; 123(8):1207-13. PubMed ID: 24311722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
    Wiestner A
    Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib (PCI-32765) in chronic lymphocytic leukemia.
    Jain N; O'Brien S
    Hematol Oncol Clin North Am; 2013 Aug; 27(4):851-60, x. PubMed ID: 23915749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.
    Cervantes-Gomez F; Kumar Patel V; Bose P; Keating MJ; Gandhi V
    Leukemia; 2016 Aug; 30(8):1803-4. PubMed ID: 27198052
    [No Abstract]   [Full Text] [Related]  

  • 14. [Ibrutinib in the treatment of chronic lymphocytic leukemia and other B-cell malignancies].
    Wang M; Xu W; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):245-9. PubMed ID: 24598688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
    JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bruton's tyrosine kinase (BTK) inhibitors in clinical trials.
    Burger JA
    Curr Hematol Malig Rep; 2014 Mar; 9(1):44-9. PubMed ID: 24357428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ibrutinib: A new drug of B-cell malignancies].
    Thieblemont C
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
    Barr PM; Brown JR; Hillmen P; O'Brien S; Barrientos JC; Reddy NM; Coutre S; Mulligan SP; Jaeger U; Furman RR; Cymbalista F; Montillo M; Dearden C; Robak T; Moreno C; Pagel JM; Burger JA; Suzuki S; Sukbuntherng J; Cole G; James DF; Byrd JC
    Blood; 2017 May; 129(19):2612-2615. PubMed ID: 28373262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
    Sharma S; Galanina N; Guo A; Lee J; Kadri S; Van Slambrouck C; Long B; Wang W; Ming M; Furtado LV; Segal JP; Stock W; Venkataraman G; Tang WJ; Lu P; Wang YL
    Oncotarget; 2016 Oct; 7(42):68833-68841. PubMed ID: 27626698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibrutinib in B lymphoid malignancies.
    Smith MR
    Expert Opin Pharmacother; 2015; 16(12):1879-87. PubMed ID: 26165513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.